Montelukast sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525716

CAS#: 151767-02-1 (sodium)

Description: Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. Montelukast is a CysLT1 antagonist; it blocks the action of leukotriene D4 (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene and results in less inflammation.

Chemical Structure

Montelukast sodium
CAS# 151767-02-1 (sodium)

Theoretical Analysis

MedKoo Cat#: 525716
Name: Montelukast sodium
CAS#: 151767-02-1 (sodium)
Chemical Formula: C35H35ClNNaO3S
Exact Mass:
Molecular Weight: 608.16877
Elemental Analysis: C, 69.12; H, 5.80; Cl, 5.83; N, 2.30; Na, 3.78; O, 7.89; S, 5.27

Price and Availability

Size Price Availability Quantity
1.0g USD 150.0 Same Day
5.0g USD 450.0 Same Day
10.0g USD 850.0 Same Day
25.0g USD 1350.0 Same Day
100.0g USD 2950.0 Same Day
500.0g USD 5850.0 2 Weeks
Bulk inquiry

Related CAS #: 151767-02-1 (sodium)   158966-92-8 (free acid)    

Synonym: MK-476; MK476; MK 476; Montelukast sodium; trade names Singulair; Montelo-10; Monteflo; Lukotas; Lumona.

IUPAC/Chemical Name: sodium (R,E)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetate


InChi Code: InChI=1S/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/q;+1/p-1/b15-10+;/t32-;/m1./s1

SMILES Code: CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)[O-])O.[Na+]

Appearance: White to off-white

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in 1:9 EtOH:PBS (pH 7.2), EtOH, DMSO, and DMF

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO or water

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Soluble in DMSO 30.0 49.4

Preparing Stock Solutions

The following data is based on the product molecular weight 608.16877 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Bush A. Montelukast in paediatric asthma: where we are now and what still needs to be done? Paediatr Respir Rev. 2015 Mar;16(2):97-100. doi: 10.1016/j.prrv.2014.10.007. Epub 2014 Dec 12. Review. PubMed PMID: 25499571.

2: Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology. 2014;94(1-2):60-70. doi: 10.1159/000366164. Epub 2014 Sep 2. Review. PubMed PMID: 25196099.

3: Hon KL, Leung TF, Leung AK. Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses? Drug Des Devel Ther. 2014 Jun 26;8:839-50. doi: 10.2147/DDDT.S39100. eCollection 2014. Review. PubMed PMID: 25061277; PubMed Central PMCID: PMC4079631.

4: Zhang HP, Jia CE, Lv Y, Gibson PG, Wang G. Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis. Allergy Asthma Proc. 2014 Jul-Aug;35(4):278-87. doi: 10.2500/aap.2014.35.3745. Review. PubMed PMID: 24992547.

5: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jan 17. Available from PubMed PMID: 24741731.

6: Matsuse H, Kohno S. Leukotriene receptor antagonists pranlukast and montelukast for treating asthma. Expert Opin Pharmacother. 2014 Feb;15(3):353-63. doi: 10.1517/14656566.2014.872241. Epub 2013 Dec 19. Review. PubMed PMID: 24350802.

7: Smith TL, Sautter NB. Is montelukast indicated for treatment of chronic rhinosinusitis with polyposis? Laryngoscope. 2014 Aug;124(8):1735-6. doi: 10.1002/lary.24477. Epub 2013 Dec 10. Review. PubMed PMID: 24338615.

8: Yilmaz O, Altintas D, Rondon C, Cingi C, Oghan F. Effectiveness of montelukast in pediatric patients with allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2013 Dec;77(12):1922-4. doi: 10.1016/j.ijporl.2013.10.006. Epub 2013 Oct 19. Review. PubMed PMID: 24210867.

9: Scichilone N, Battaglia S, Benfante A, Bellia V. Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients. Clin Interv Aging. 2013;8:1329-37. doi: 10.2147/CIA.S35977. Epub 2013 Oct 2. Review. PubMed PMID: 24124355; PubMed Central PMCID: PMC3794872.

10: Pacheco Y, Freymond N, Devouassoux G. Impact of montelukast on asthma associated with rhinitis, and other triggers and co-morbidities. J Asthma. 2014 Feb;51(1):1-17. doi: 10.3109/02770903.2013.822081. Epub 2013 Aug 2. Review. PubMed PMID: 23834429.

11: Massingham K, Fox S, Smaldone A. Asthma therapy in pediatric patients: a systematic review of treatment with montelukast versus inhaled corticosteroids. J Pediatr Health Care. 2014 Jan-Feb;28(1):51-62. doi: 10.1016/j.pedhc.2012.11.005. Epub 2013 Jan 9. Review. PubMed PMID: 23312367.

12: Ducharme FM, Noya FJ, Allen-Ramey FC, Maiese EM, Gingras J, Blais L. Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors. Curr Med Res Opin. 2012 Jan;28(1):111-9. doi: 10.1185/03007995.2011.640668. Epub 2011 Dec 16. Review. PubMed PMID: 22077107.

13: Amlani S, Nadarajah T, McIvor RA. Montelukast for the treatment of asthma in the adult population. Expert Opin Pharmacother. 2011 Sep;12(13):2119-28. doi: 10.1517/14656566.2011.600689. Epub 2011 Jul 22. Review. PubMed PMID: 21777174.

14: Bellecoste V, Devouassoux G, Pacheco Y. [Montelukast in the treatment of mild to moderate persistent asthma]. Rev Mal Respir. 2011 Jun;28(6):706-29. doi: 10.1016/j.rmr.2010.12.008. Epub 2011 May 17. Review. French. PubMed PMID: 21742233.

15: Tintinger GR, Feldman C, Theron AJ, Anderson R. Montelukast: more than a cysteinyl leukotriene receptor antagonist? ScientificWorldJournal. 2010 Dec 14;10:2403-13. doi: 10.1100/tsw.2010.229. Review. PubMed PMID: 21170491.

16: Adsule SM, Misra D. Long term treatment with montelukast and levocetirizine combination in persistent allergic rhinitis: review of recent evidence. J Indian Med Assoc. 2010 Jun;108(6):381-2. Review. PubMed PMID: 21121394.

17: Capsomidis A, Tighe M. Archimedes. Question 2. Is oral montelukast beneficial in treating acute asthma exacerbations in children? Arch Dis Child. 2010 Nov;95(11):948-50. doi: 10.1136/adc.2010.200048. Review. PubMed PMID: 20980280.

18: Castro-Rodriguez JA, Rodrigo GJ. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis. Arch Dis Child. 2010 May;95(5):365-70. doi: 10.1136/adc.2009.169177. Epub 2009 Nov 27. Review. PubMed PMID: 19946008.

19: Bousquet J, Demoly P, Humbert M. Montelukast in guidelines and beyond. Adv Ther. 2009 Jun;26(6):575-87. doi: 10.1007/s12325-009-0038-1. Epub 2009 Jun 26. Review. PubMed PMID: 19562275.

20: Manalai P, Woo JM, Postolache TT. Suicidality and montelukast. Expert Opin Drug Saf. 2009 May;8(3):273-82. doi: 10.1517/14740330902932688. Review. PubMed PMID: 19505261.

Additional Information

Related CAS#
CAS#151767-02-1 (Montelukast sodium salt);
CAS#158966-92-8 (Montelukast free acid).